Leponex

Clozapine, the active ingredient in Leponex, is an atypical antipsychotic presented as an oral tablet for oral use. It is indicated for patients with treatment‑resistant schizophrenia and schizoaffective disorder. GNH USA supplies Leponex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leponex (clozapine) is used in the management of psychotic disorders that are resistant to standard therapy.

- Schizophrenia (treatment‑resistant): reduces psychotic symptoms and relapse risk in patients who have not responded adequately to other antipsychotics. - Schizoaffective disorder: improves mood and psychotic features when other treatments are insufficient.

Clozapine may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Sedation: drowsiness or feeling unusually sleepy. - Weight gain: increase in body weight over time. - Constipation: reduced bowel movements. - Excessive salivation: increased saliva production.

Serious or Rare Side Effects: - Agranulocytosis: severe drop in white blood cells requiring regular blood monitoring. - Myocarditis: inflammation of the heart muscle, potentially life‑threatening. - Seizures: heightened risk, especially at higher doses.

Before initiating clozapine therapy, several safety measures should be observed.

- Blood monitoring: Perform regular complete blood counts to detect agranulocytosis. - Cardiac assessment: Baseline and periodic ECGs for myocarditis risk. - Seizure risk: Evaluate history and avoid high doses in patients with seizure disorders. - Metabolic monitoring: Track weight, glucose, and lipids due to metabolic effects. - Drug interactions: Review concomitant medications that may affect clozapine levels. - Store at ambient temperature: Keep below 25 °C in the original pack, protect from moisture.

Clozapine interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine): can markedly increase clozapine plasma levels. - CYP1A2 inducers (e.g., carbamazepine, smoking): can reduce efficacy. - Concomitant use with other myelosuppressive agents: heightens risk of agranulocytosis.

Moderate Interactions (Monitor Closely): - Benzodiazepines: may enhance sedation and respiratory depression. - Anticholinergic drugs: may worsen constipation. - QT‑prolonging agents: increase risk of cardiac arrhythmias.